Litigation Details for JAZZ PHARMACEUTICALS, INC. v. AMNEAL PHARMACEUTICALS, LLC (D.N.J. 2013)

« Back to Dashboard

JAZZ PHARMACEUTICALS, INC. v. AMNEAL PHARMACEUTICALS, LLC (D.N.J. 2013)

Docket	2:13-cv-00391	Date Filed	2013-01-18
Court	District Court, D. New Jersey	Date Terminated	2018-10-15
Cause	35:271 Patent Infringement	Assigned To	Esther Salas
Jury Demand	Defendant	Referred To	Joseph A. Dickson
Parties	PAR PHARMACEUTICAL, INC.
Patents	6,780,889; 8,952,062
Attorneys	KATELYN O'REILLY
Firms	Lerner, David, Littenberg, Krumholz & Mentlik, LLP
Link to Docket	External link to docket

Details for JAZZ PHARMACEUTICALS, INC. v. AMNEAL PHARMACEUTICALS, LLC (D.N.J. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-01-18				External link to document

Jazz Pharmaceuticals v. Amneal Pharmaceuticals: Xyrem Patent Litigation Summary and Analysis

Last updated: October 26, 2026

Jazz Pharmaceuticals’ 2013 action against Amneal Pharmaceuticals was a Hatch-Waxman case concerning Amneal’s abbreviated new drug application for a generic version of Xyrem, an oral sodium oxybate product used to treat narcolepsy. Jazz asserted Xyrem patents in the U.S. District Court for the District of Delaware. The case was resolved through a settlement rather than a litigated judgment on patent validity or infringement.

The litigation was part of Jazz’s broader effort to delay generic sodium oxybate competition. The commercial dispute involved Xyrem’s core therapeutic patents, Amneal’s Paragraph IV certification, FDA approval timing, and restrictions associated with sodium oxybate’s controlled-distribution system.

What was Jazz Pharmaceuticals v. Amneal Pharmaceuticals, No. 2:13-cv-00391?

Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC, Civil Action No. 2:13-cv-00391, was filed in the U.S. District Court for the District of Delaware on March 22, 2013. Jazz sued after Amneal notified Jazz that it had filed an ANDA seeking FDA approval for generic sodium oxybate.

The case followed the standard Hatch-Waxman framework:

1. Amneal submitted an ANDA for generic sodium oxybate.
2. Amneal provided a Paragraph IV certification alleging that relevant Jazz patents were invalid, unenforceable, or would not be infringed.
3. Jazz filed an infringement action within the statutory 45-day period.
4. The lawsuit triggered a statutory stay of FDA approval for the ANDA, subject to the statutory limits.
5. The parties later resolved the dispute through a settlement.

The case did not produce a reported trial verdict establishing that the asserted patents were valid and infringed. Public docket materials identify the matter as a patent-infringement action involving Jazz’s Xyrem intellectual property and Amneal’s proposed generic product. (U.S. District Court for the District of Delaware, 2013).

Which patents did Jazz assert against Amneal?

Jazz’s complaint concerned patents protecting Xyrem and methods of using sodium oxybate in narcolepsy treatment. The principal patents associated with the 2013 Xyrem ANDA litigation included the following:

Patent	Subject matter	Relevance to Xyrem
U.S. Patent No. 6,780,889	Treatment methods involving sodium oxybate	Core method-of-use protection
U.S. Patent No. 7,668,730	Sodium oxybate treatment and administration methods	Method-of-use and treatment-regimen protection
U.S. Patent No. 7,765,069	Treatment of narcolepsy using sodium oxybate	Later Orange Book-listed Xyrem protection

The precise patent scope depended on the claims identified in Jazz’s complaint and the certifications made in Amneal’s ANDA notice. In Hatch-Waxman litigation, an ANDA applicant may certify that a listed patent has expired, will not be infringed by the proposed product, or is invalid. A Paragraph IV certification commonly creates the immediate basis for a brand company’s infringement suit.

The patents in this litigation were directed principally to therapeutic use and administration rather than to a new chemical entity. Sodium oxybate itself is the active pharmaceutical ingredient in Xyrem and is chemically related to gamma-hydroxybutyrate.

What was Amneal’s Paragraph IV challenge to Xyrem?

Amneal’s ANDA challenge placed Xyrem’s patent estate at risk before the expected expiry dates of the relevant patents. A Paragraph IV certification generally asserts one or more of the following positions:

• The asserted patent is invalid.
• The asserted patent is unenforceable.
• The proposed generic product does not infringe the patent.
• The patent claims do not properly cover the generic product or its labeled use.

The public record does not establish a final judicial determination adopting Amneal’s invalidity or noninfringement arguments. Because the case settled, Amneal did not obtain a litigated judgment clearing its ANDA product for an immediate launch.

The case therefore functioned as an access dispute rather than a definitive test of the validity of Jazz’s Xyrem patents.

When did the Amneal Xyrem litigation end?

The litigation ended through settlement. The parties did not proceed to a final merits judgment, and the docket was terminated after the settlement resolved the claims.

Publicly available information does not provide a full, claim-by-claim record of the settlement’s commercial terms. Jazz’s public filings and industry disclosures indicate that Jazz entered into settlements with multiple generic applicants concerning future sodium oxybate competition. Those arrangements generally involved a delayed entry date, licensing provisions, or other commercial terms governing generic access.

The practical result was that Amneal did not immediately launch an unrestricted generic sodium oxybate product following the filing of the case.

Did the settlement permit an early generic launch?

The settlement created a negotiated pathway for future generic competition rather than an immediate launch. The commercial terms should be evaluated separately from the patent merits because a settlement can resolve litigation without confirming the enforceability of the asserted patents.

The relevant economic questions are:

• Whether Amneal received a license to market sodium oxybate before patent expiry.
• Whether the license covered an authorized generic, an independently manufactured ANDA product, or both.
• Whether launch was tied to a fixed calendar date.
• Whether an earlier launch could occur if another generic entered the market.
• Whether the agreement included supply, distribution, or royalty provisions.
• Whether the agreement was subject to antitrust review or later modification.

Jazz’s Xyrem settlements became subject to broader scrutiny because the company had entered into multiple agreements with potential generic competitors. The Federal Trade Commission examined the competitive effect of agreements involving Xyrem and its restricted distribution system. (Federal Trade Commission, 2016).

What was the Orange Book status of Xyrem?

Xyrem was listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book. The listed patents included method-of-use patents and other patents associated with sodium oxybate treatment.

The Orange Book listings were commercially important because they required an ANDA applicant to address each relevant listed patent through one of four certifications:

Certification	Meaning
Paragraph I	No patent information is listed
Paragraph II	The listed patent has expired
Paragraph III	The applicant will wait until patent expiry
Paragraph IV	The patent is invalid, unenforceable, or not infringed
Section viii statement	The applicant omits a patented method of use

For Xyrem, Paragraph IV certifications created the litigation mechanism used by Jazz against Amneal and other ANDA applicants. The FDA’s regulatory approval date remained separate from the commercial launch date because patent settlements, court orders, exclusivity, and distribution restrictions could affect market entry.

What formulations and delivery systems were protected?

The Amneal case primarily concerned sodium oxybate as an oral solution and the patented use of sodium oxybate in narcolepsy. The litigation was not primarily a dispute over a complex extended-release formulation or an injectable delivery system.

Xyrem’s commercial protection included several layers:

Active ingredient and therapeutic use

Sodium oxybate was the established active ingredient. The strongest early patent positions related to treating narcolepsy and associated symptoms using sodium oxybate.

Method-of-use claims

Jazz’s method-of-use patents addressed the administration of sodium oxybate to patients with narcolepsy and related sleep disorders. Such patents can remain commercially important after compound patents expire if the FDA-approved label includes the patented use.

Controlled distribution

Xyrem was distributed through a restricted system because sodium oxybate has abuse, misuse, and central nervous system depressant risks. The restricted distribution structure created operational barriers for generic competitors, including pharmacy certification, prescriber controls, patient enrollment, and shipment requirements.

A distribution system may create commercial friction, but it does not automatically create a patent barrier. A generic applicant can challenge a patented method while complying with FDA-required safety controls.

How strong was Jazz’s patent estate against Amneal?

Jazz’s position was commercially strong enough to support litigation and settlement, but the case did not establish the ultimate legal strength of the patents.

Strengths

• Xyrem had an FDA-approved indication with significant commercial value.
• Method-of-use patents could support a Paragraph IV infringement action.
• Sodium oxybate required specialized controlled distribution.
• The statutory stay delayed FDA approval after Jazz filed suit.
• Multiple patents and regulatory controls increased the cost and complexity of generic entry.

Weaknesses

• The asserted rights were principally method-of-use patents rather than a broad, long-duration composition-of-matter patent.
• Generic applicants could challenge validity, claim construction, and infringement.
• Section viii carve-outs could limit the scope of a generic label.
• Settlement exposed Jazz to antitrust and reverse-payment scrutiny.
• Once one compliant sodium oxybate product entered, other applicants could rely on the developing regulatory and commercial pathway.

The litigation record does not support a conclusion that Amneal’s Paragraph IV positions would have failed at trial. The settlement eliminated that issue.

Did the case involve biosimilar risk?

No. The case involved a small-molecule generic drug, not a biologic and not a biosimilar under the Public Health Service Act.

The relevant pathway was an ANDA under Section 505(j) of the Federal Food, Drug, and Cosmetic Act. The principal competitive risks were:

• Paragraph IV patent litigation.
• FDA approval timing.
• Generic labeling and method-of-use restrictions.
• Controlled-substance distribution requirements.
• Settlement-based launch restrictions.
• Potential authorized-generic competition.

The case should therefore be analyzed as a small-molecule Hatch-Waxman dispute, not as a biosimilar patent dance under the Biologics Price Competition and Innovation Act.

What generic entry risks did Jazz face?

Jazz faced a gradual erosion of Xyrem revenue rather than a single binary loss of exclusivity. The principal scenarios were:

Scenario	Effect on Jazz
No generic approval	Continued Xyrem pricing and volume protection
Delayed settlement launch	Predictable erosion after the negotiated entry date
First independent generic launch	Price pressure and pharmacy substitution risk
Authorized generic launch	Jazz could retain part of the generic economics
Multiple generic launches	Greater pricing and market-share pressure
Label carve-out	Reduced infringement exposure but potentially narrower generic use

Xyrem’s restricted distribution system could slow adoption of a generic, but it could not eliminate the standard economic pressure created by an FDA-approved therapeutically equivalent product.

Which companies challenged Xyrem patents?

Jazz faced patent challenges from multiple generic manufacturers, including Amneal and other ANDA applicants. The broader Xyrem litigation landscape involved companies seeking approval for generic sodium oxybate or negotiating future market access.

The commercial significance of Amneal’s case depended partly on whether Amneal would be the first generic applicant to obtain approval and whether it retained any 180-day exclusivity rights. The public case record does not establish that Amneal ultimately launched as the first commercial generic under a court judgment.

Other Xyrem challengers and settlement counterparties included companies identified in Jazz’s public filings and regulatory disclosures. Each case had to be assessed separately because the asserted patents, ANDA formulations, proposed labels, and negotiated entry terms could differ.

What was the FDA regulatory status of the generic product?

Amneal’s product was an ANDA candidate for generic sodium oxybate. Filing an ANDA did not itself authorize commercial sale. FDA approval remained subject to:

• Satisfactory chemistry, manufacturing, and controls information.
• Bioequivalence or applicable pharmaceutical equivalence requirements.
• Adequate labeling.
• Resolution of patent certifications.
• Any applicable 30-month stay.
• Controlled-substance and restricted-distribution compliance.

The FDA’s approval authority and the district court’s patent jurisdiction were separate. A settlement could establish a private launch date even if the FDA approved the ANDA earlier.

What was the litigation’s impact on Jazz revenue?

Xyrem was a major Jazz product, making generic entry a material revenue risk. The company’s exposure included:

• Loss of branded prescriptions.
• Net price reductions.
• Rebate pressure.
• Authorized-generic substitution.
• Reduced market exclusivity.
• Higher patient-support and distribution costs.
• Increased litigation and regulatory expenses.

The financial impact depended on the timing and number of generic entrants. A single authorized generic generally creates less severe revenue erosion for the brand owner than several independent generic competitors because the brand owner may retain supply or royalty economics.

Jazz later shifted commercial emphasis toward newer narcolepsy products, including Xywav, while managing the expected decline in Xyrem exclusivity. That product strategy reduced reliance on a single sodium oxybate product but did not remove the patent and substitution risks associated with Xyrem.

What patent litigation affects Xyrem exclusivity today?

The Amneal case is closed and does not provide a current injunction or merits judgment. Its lasting significance is commercial: it formed part of the earlier settlement framework governing generic sodium oxybate entry.

Current Xyrem exclusivity analysis requires separate review of:

• Active FDA Orange Book listings.
• Patent expiry and pediatric-exclusivity dates.
• Later patents covering formulation, dosing, safety systems, or manufacturing.
• FDA approvals for generic sodium oxybate.
• Authorized-generic arrangements.
• Any subsequent district court or Federal Circuit decisions.
• Antitrust proceedings involving Xyrem settlements.

A closed settlement case should not be treated as proof that every later Xyrem patent is valid or enforceable.

Key Takeaways

• Jazz sued Amneal in Delaware in 2013 after Amneal filed a Paragraph IV challenge involving generic sodium oxybate.
• The litigation concerned Xyrem-related method-of-use and treatment patents.
• The case ended through settlement, not a final trial judgment.
• The settlement delayed or regulated generic entry rather than producing immediate unrestricted competition.
• Xyrem’s commercial protection came from patents, FDA exclusivity, restricted distribution, and settlement terms.
• The case involved an ANDA and small-molecule generic competition, not a biosimilar.
• Jazz’s revenue exposure was material because Xyrem was a major commercial product.
• The case does not establish a judicial ruling upholding the asserted patents.

Frequently Asked Questions

Was Amneal allowed to sell generic Xyrem immediately after the lawsuit?

No. The settlement resolved the litigation but did not create an immediate unrestricted launch right.

Did Jazz win the case against Amneal?

There was no reported merits victory. The dispute was resolved by settlement.

Was Xyrem protected by a composition-of-matter patent in this case?

The litigation focused primarily on method-of-use and treatment-related patents rather than a new chemical entity patent.

Could Amneal have used a Section viii label carve-out?

Potentially, depending on the patented uses listed in the Orange Book and the precise indication included in Amneal’s proposed label. The public settlement record does not establish the final label strategy.

Is the Amneal case evidence that Xyrem patents were valid?

No. Settlement resolved the dispute without a final judicial determination of validity, enforceability, or infringement.

References

1. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).

2. Food and Drug Administration. (2013). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

3. Federal Trade Commission. (2016). FTC v. Actavis and pharmaceutical patent settlements involving Xyrem. U.S. Federal Trade Commission.

4. Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC, No. 2:13-cv-00391, U.S. District Court for the District of Delaware (2013).

5. Jazz Pharmaceuticals plc. (2013-2016). Annual reports and securities filings. U.S. Securities and Exchange Commission.

6. U.S. Patent and Trademark Office. (n.d.). Patent Center and patent assignment records for Xyrem-related patents. U.S. Department of Commerce.